Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Clearpoint Neuro Inc (OQ:CLPT)

Business Focus: Advanced Medical Equipment & Technology

INK Edge Outlook

Insider Chart - Past 6 Months

Insider Filings

Latest 10 SEC Form 4 filings for CLPT*US within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Mar 19, 2024 08:07 ET
ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner PTC Therapeutics on completion of its BLA submission...
Read full article
Mar 12, 2024 16:05 ET
ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results
ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its fourth quarter and full-year ended...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.89
--
--
Price to Sales - TTM
7.57
3.03
3.32
Price to Book - most recent quarter
7.82
2.23
2.21
Price to Cash Flow per share - TTM
--
20.91
14.62
Price to Free Cash Flow per share - TTM
--
33.82
24.76
See all valuations

Business Summary

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology

ClearPoint Neuro, Inc. is a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product is the ClearPoint Neuro Navigation System. Its initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in a magnetic resonance imaging (MRI) suite. The ClearPoint Array Neuro Navigation System and its principal disposable component is designed to be deployed in an operating room setting while also being usable in an MRI suite. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. It also provides solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide.

See business summary

 

Twitter

Search (past week) for $CLPT

  • No tweets found